First Choice Neurology Research Center 23 Clinical Trials
First Choice Neurology Research Center 23 offers clinical trials for Alzheimer's disease, Parkinson's disease, migraines, pain, and other neurological disorders.
Apheleia-001 Study by GAP
Ages 50-90. Identify and characterize participants with reported memory complaints and/or cognitive impairment using demographic information, clinical history, brief cognitive assessments, and blood-based biomarkers to determine the probability of randomization into a therapeutic AD clinical trial.
Abbv-916 Study by Abbvie
Ages 50-90. To evaluate the efficacy and pharmacodynamics of ABBV-916 following multiple ascending doses, administered Q4W intravenously in subjects with early AD. And to evaluate the safety, tolerability, and amyloid reduction associated with ABBV-916 after repeated intravenous administrations in subjects with early AD.
Ages 55-85. A 52-week, Phase 2 Clinical Study to evaluate the safety and efficacy of GV1001. Administered subcutaneously for the treatment of mild to moderate Alzheimer’s Disease. In a completed Phase 2 study conducted in Korea, GV1001 showed significant improvement in change from baseline of severe impairment battery score. At week 24 and demonstrated a clinically acceptable safety profile in patients with moderate to severe AD.
Hope study by Cognito
Ages 50-90. This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's disease. Approximately 530 subjects will be randomized to 12 months of daily treatment with either Active or Sham Sensory
Stimulation Systems. Efficacy will be measured using the Alzheimer's Disease Cooperative StudyActivities of Daily Living (ADCS-ADL) assessment and a combined statistical test (CST) of the ADCS-ADL and the Mini-Mental State Exam (MMSE).
LAKC study by Eli Lilly
TRAILRUNNER-ALZ 1 is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Remternetug in participants with early symptomatic AD. Initially, 600 participants will enroll in the double-blind treatment period. Participants in the double-blind treatment period will receive Remternetug or placebo administered via subcutaneous injection or intravenous infusion.
Following the 52-week main study period, participants will continue participation for up to an additional 52 weeks in an extension period. Participants who previously received Remternetug will receive placebo and participants who previously received placebo will receive Remternetug. Thus, all participants will receive Remternetug if they complete the study.
Parkinson’s Disease Clinical Studies
Study participants must be 35 to 80 years of age PD0060 is designed to provide proof-of-concept for the efficacy of UCB0022 in study participants with advanced Parkinson’s disease (PD). To demonstrate the superiority of UCB0022 as an adjunctive treatment to a stable dose of SoC (including at least levodopa therapy) over placebo with regard to motor fluctuations in study participants with advanced PD.
To create a genetic data and sample repository for PD-specific genetic tests for future research use. To provide clinical genetic testing for people with Parkinson’s disease and eligible family members.
The purpose of this study is to assess the efficacy and safety of Dysport® (hereafter referred to as Dysport) compared with placebo in the prevention of chronic migraine in adult participants. In clinical studies, botulinum toxin type A (BoNT-A) has been shown to reduce migraine headaches and associated disease burden in adults with chronic migraine BoNT-A inhibits vesicle-mediated neurotransmitters that are understood to be important in the pathogenesis of migraine, including calcitonin gene-related peptide (CGRP), and may also have other afferent targets that result in an attenuation of migraine triggers.
A Phase 2, randomized, double-blind, placebo-controlled, parallel-design study of the efficacy and safety of VX-548 in subjects with painful Lumbosacral Radiculopathy. Change from baseline in the weekly average of daily leg pain intensity on a numeric pain rating scale (NPRS) at week 12.
Contact First Choice Neurology Research Center 23
Aventura Neurology, LLC
21000 NE 28th Ave., #205
Aventura, FL 33180
Main Phone: - 1-833-732-2484
Cell Phone: (786) 431-2507
Fax: (954) 900-1623